Home

Lynne Marie Sullivan

CIK 1727640 · CFO & Head of Corp. Dev. · last filed 2026-06-11

Lynne Marie Sullivan is a CFO & Head of Corp. Dev. who has filed 38 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for SLDB, was dated Jun 11, 2026. Across all open-market trades the lifetime net is +$26.3K, making them a net buyer over the disclosed history. 7 SEC filings were submitted jointly with Inozyme Pharma, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

38

Lifetime Open-Market Net

$26.3K

Filer Profile

Reported Address
C/O SOLID BIOSCIENCES, LLC
141 PORTLAND STREET, FIFTH FLOOR
CAMBRIDGE, MA 02139
Related Filers
Inozyme Pharma, Inc. — 7 joint filings, latest 2025-07-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SLDB Director — $7.30 — $0 11 2026-06-11
Unity Biotechnology, Inc. (UBX) Delisted CFO & Head of Corp. Dev. 98,905 $0.20 $19.8K -$23.7K 13 2025-04-03
Inozyme Pharma, Inc. (INZY) Delisted Director — $4.00 — $0 5 2024-06-20
BiomX Inc. (PHGE.WS) Delisted Director 12,500 $0.01 $110 $50.0K 5 2023-03-03
Adicet Bio, Inc. (TORC) Delisted Director — — — $0 2 2020-06-05

Recent Filings

38 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-11 SLDB Grant (A) — $0 EDGAR
2025-07-03 — Disp (D) — $0
2025-06-13 SLDB Grant (A) — $0 EDGAR
2025-04-03 Unity Biotechnology, Inc. (UBX) Delisted Sell (S) −21,867 -$22.5K EDGAR
2025-04-03 Unity Biotechnology, Inc. (UBX) Delisted Notice (144) −21,867 -$22.4K EDGAR
2025-03-31 Unity Biotechnology, Inc. (UBX) Delisted Grant (A) +65,000 $0 EDGAR
2025-02-05 Unity Biotechnology, Inc. (UBX) Delisted Sell (S) −153 -$341 EDGAR
2025-01-23 Unity Biotechnology, Inc. (UBX) Delisted Grant (A) — $0 EDGAR
2024-11-06 Unity Biotechnology, Inc. (UBX) Delisted Sell (S) −136 -$175 EDGAR
2024-08-06 Unity Biotechnology, Inc. (UBX) Delisted Sell (S) −139 -$213 EDGAR
Showing 1–10 of 38
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.